Login / Signup

Impact of the COVID-19 pandemic on the treatment of acute cholangitis caused by choledocholithiasis: A single-center retrospective study in Japan.

Jun-Ichi HanataniKoh KitagawaFumimasa TomookaShohei AsadaAkira MitoroYukihisa FujinagaNorihisa NishimuraShinya SatoAkihiko ShibamotoYuki FujimotoTakahiro KuboSatoshi IwaiYuki TsujiTadashi NamisakiTakemi AkahaneKosuke KajiMisako TanakaAritoshi KoizumiNobuyuki YoriokaTakuya MatsudaHiroyuki MasudaMasayoshi TakamiMayuko KikuchiMariya KawanishiKazutaka OhokaDaisuke WatanabeAkane KawasakiHitoshi Yoshiji
Published in: DEN open (2024)
Although our hospital provides tertiary care, the number of patients with cholangitis in good general condition and no underlying disease increased after the state of emergency declaration. The COVID-19 pandemic resulted in an increase in the number of single-stage endoscopic treatments and shortened hospital stays for patients with acute cholangitis caused by choledocholithiasis. No safety issues with ERCP were detected, even during the pandemic.
Keyphrases
  • tertiary care
  • healthcare
  • ulcerative colitis
  • sars cov
  • emergency department
  • public health
  • liver failure
  • acute care
  • coronavirus disease
  • adverse drug
  • respiratory failure
  • drug induced
  • hepatitis b virus